Experience in our field.
World-class phage isolation
High throughput methods for multiple samples to be screened simultaneously. With the experience and ability working with:
Antimicrobial resistant strains
Difficult to culture targets
Slow-growing environmental bacteria
Strict anaerobes
Highly purified and curated library of clinically and commercially relevant strains of bacteria and phage.
Track-record of isolating & identifying highly virulent phages
Efficiently selecting phages to develop treatments combining the most effective phage cocktail, with methods ensuring efficacy and safety including:
Yield
Efficiency of plating
Passaging
Routine in-house sequencing
Lab scale/Batch production
Once the phages are identified, isolated, screened and selected, they must be produced to appropriate quantities and standards
The company has the capability to grow phages at lab scale in a batch process, allowing for scale up production levels to supply.
We can do this due to the in-house expertise in GMP manufacturing, and partnership with GMP manufacturing facilities.
Patented method of formulating phages
Providing a truly unique and novel formulation technology, that allows the development of products at a mass scale that other phage companies cannot do.
Immobilisation gives a number of advantages:
The localisation of phages on a product
Enhancing the stability of phages to support larger scale manufacturing and supply
We believe that every person and animal has the right to live a healthy, life free from disease and suffering. And believe we have a critical role to play in achieving this goal through tackling the growing Anti-microbial Resistance (AMR) problem, and it is our responsibility to strive for excellence in everything we do.
Recognising this enormous responsibility, we are committed to upholding the highest standards of ethics, integrity, and social responsibility.
We value research and development as a cornerstone of our work. Are committed to pushing boundaries of science, exploring new technologies and approaches, and collaborating with the best minds of academia and industry to drive innovation forward.
We will always put the needs of the patient at the centre of everything we do. We will listen to their needs and work tirelessly to develop treatments that meet their specific needs fast, ensuring their safety and well-being.
We will pursue scientific excellence in all aspects of our work. We will conduct rigorous research, use the latest technologies, and collaborate with the brightest minds to develop innovative treatments that have the potential to transform patients’ lives.
We will foster a culture of innovation that encourages creativity, risk taking and continuous learning. We will empower employees, think outside the box, and pursue bold ideas that have the potential to change the world.
We will embrace diversity and inclusion in all aspects of our work. We will create an environment that celebrates differences, promotes a sense of belonging for all employees, regardless of their background, race, gender, or sexual orientation.
We will operate with integrity and transparency in all our dealings. We will be honest, open, and ethical in our interactions with patients, healthcare providers, regulators, partners, and the wider community.
Established in 2010 and originating from a groundbreaking idea for a bacteria-free container. With venture capital support and a patent filed in 2003, the company tested the technology using a corona discharge machine. This machine facilitated the validation of the phage immobilisation technology.
Following patent filing in 2003, and with venture capital funding, the technology was tested. A corona discharge machine, provided by the car polish company Glaze, enabled them to validate the phage immobilisation technology.
We further enhanced the innovative plasma-based immobilisation technology, making it scalable, versatile, cost-effective, fast, and eco-friendly compared to chemical methods. The outcome is scalable immobilised phage formulations with sustained antibacterial activity, even after drying, and stability in diverse real-world environments.
The company has continued to build a substantial patent portfolio, encompassing the latest developments in the immobilisation technology and specific application areas.
Focused on addressing antimicrobial resistance (AMR) and improving both human and animal health while capitalising on our considerable expertise and knowledge in the development of effective and sustainable phage-based solutions, ensuring an unwavering commitment towards our extensive and innovative work with phages, and a focused strategy as the UK’s leading end-to-end phage company.
Welcome to the beating heart of innovation
Together we are bringing “The Age of the Phage”
